Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

The study is a Phase 2 clinical trial of the drug cirtuvivint as a second-line treatment for advanced soft tissue sarcomas. The study is being conducted in Spain and is expected to enroll approximately 25 patients in total. The primary objective of this Phase 2 study is to evaluate the efficacy of treatment with cirtuvivint. Cirtuvivint is an anti-cancer medication developed by the U.S. company Biosplice Therapeutics, Inc. This drug is an inhibitor of the enzymes CLK1-4 and DYRK1-4 (molecules involved in the cell cycle) and is administered as oral tablets. This product is still under investig

Trial Details

NCT ID
NCT07032285
Phase
PHASE2
Sponsor
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Cirtuvivint
Locations (sample)
  • Madrid, Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Patients must provide written informed consent prior to performance of any study-specific procedures and must be willing to comply with treatment a…
  • Age: 16-70 years.
  • Patients with a diagnosis of advanced unresectable soft-tissue sarcoma and not candidates for surgical rescue including only the following subtypes…
  • Metastatic/locally advanced with recent progression (\<6 months).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →